Clinical Trials Directory

Trials / Completed

CompletedNCT01141777

The Effects of Spirulina Platensis on Insulin Resistance in HIV-infected Patients

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
33 (actual)
Sponsor
Yaounde Central Hospital · Other Government
Sex
All
Age
21 Years
Healthy volunteers
Not accepted

Summary

Spirulina, a widely used food supplement, improves the lipid profile and glycemic control in people living with diabetes, suggesting that it could have some effects on insulin sensitivity. Since HIV-infected patients develop metabolic abnormalities due to the virus and/or to antiretroviral (ARV) drugs, the investigators therefore proposed to evaluate the effect that spirulina can have on HIV/HAART-associated insulin resistance

Detailed description

Even though antiretroviral therapy (ART) has dramatically improved the health of people living with HIV/AIDS, the prospect of maintaining patients long term on ART can be severely restricted by the development of serious long term effects in their metabolism. These abnormalities include dyslipidemia, lipodystrophy and disorders of glucose metabolism with insulin resistance believed to be the underlying pathophysiological mechanism. Spirulina, has recently drawn attention on its cholesterol and blood pressure lowering effects, including improvement of glycaemic control in diabetics subjects, suggesting it can have some effects on insulin sensitivity. The aim of this three month, experimental, prospective, randomised trial was to evaluate the effect of Spirulina on HIV/HAART-associated insulin resistance on 33 subjects. Primary outcome was change in insulin sensitivity during the trial, over two time periods; t=0 and t=12 weeks. The second objective was to compare between the two groups, the percentage of subjects who improved insulin sensitivity by the end of the study. Recruitment started in October 2008 and the trial ended in February 2009.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTSpirulina platensisSubjects received 19g daily of supplement averagely.This was supplied as powder daily, in packs that lasted for 2weeks each. Each subject was therefore seen every two week to obtain new stock of supplements and evaluate compliance
DIETARY_SUPPLEMENTSoya beanEach subject received 19g of supplement on average daily. Subjects were seen every two weeks to evaluate compliance and obtain a new stock.

Timeline

Start date
2008-10-01
Primary completion
2009-02-01
Completion
2009-02-01
First posted
2010-06-11
Last updated
2011-01-04

Locations

1 site across 1 country: Cameroon

Source: ClinicalTrials.gov record NCT01141777. Inclusion in this directory is not an endorsement.